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The worldwide incidence of melanoma has increased over 
the past few decades and in 2020 approximately 325 000 
new cases and more than 57 000 deaths were observed.1 In 
Australia, cutaneous melanoma is the second and third 
most commonly diagnosed cancer among men and women, 
respectively.2 Moreover, despite a lower incidence glob-
ally compared to other solid tumors, melanoma has a high 
incidence among adolescents and younger adults.1 Most 
patients with melanoma are treated with surgery alone, 
whereas radiotherapy, and systemic treatment with tar-
geted or immunotherapy, are utilized for patients with 
more advanced disease.3
Novel systemic therapies such as targeted therapy with 
BRAF inhibitors and immune checkpoint inhibitors have 
demonstrated a survival advantage in patients with advanced 
melanoma.4,5 However, these treatments are not without 
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Abstract
Purpose: Although exercise medicine is recommended to counter treatment-related side-effects and improve health-
related outcomes of patients affected by different cancers, no specific recommendations exist for patients with melanoma. 
As a result, we systematically examined the current evidence regarding the effects of physical activity and exercise on 
objectively-measured and patient-reported outcomes among patients with melanoma. Methods: Searches were conducted 
in PubMed, CINAHL, EMBASE, SPORTDiscus, and Web of Science databases. This review included published data involving 
physical activity or exercise and objectively-measured or patient-reported outcomes of patients with cutaneous melanoma. 
The quality of included studies was assessed using the McMaster University Critical Appraisal Tool for Quantitative 
Studies. Results: Six studies including 882 patients with melanoma were included. Studies presented heterogeneity of 
design with 2 cross-sectional surveys, 2 retrospective analyses, and 2 non-randomized intervention trials. No statistically 
significant change in quality of life, fatigue, physical function, cardiorespiratory fitness, body composition, psychological 
distress, cognitive function, or treatment-related side-effects were attributable to physical activity or exercise. Importantly, 
physical activity or exercise during melanoma treatment or into survivorship did not adversely impact patients/survivors. 
Conclusion: In summary, physical activity or exercise did not adversely impact quality of life, objectively-measured or 
patient-reported outcomes in patients with melanoma. In addition, there is a paucity of quality studies examining the 
effects of physical activity or exercise on patients with melanoma throughout the cancer care continuum.
Keywords
melanoma, skin cancer, physical activity, exercise, quality of life, health-related outcomes
Submitted May 10, 2021; revised July 23, 2021; accepted August 3, 2021
2 Integrative Cancer Therapies 
risk and adverse effects; dermatological, gastrointestinal, 
hepatic, and endocrine toxicities are frequently experienced 
by patients.5-7 Immune-related adverse events (irAEs) 
resulting from treatment with immune checkpoint inhibitors 
are distinctly different from the classical chemotherapy-
related toxicities. However, several symptoms such as 
fatigue and weakness, diarrhea, arthralgia, and reductions in 
muscle mass are common, substantially affecting quality of 
life (QoL) and wellbeing of the patients during and poten-
tially following the completion of treatment.6,8,9 
Furthermore, patients with cancer also experience substan-
tial reductions in muscle mass (ie, sarcopenia) as a result of 
aging and physical inactivity and this has been shown to be 
associated with poorer cancer treatment outcomes.8
Physical activity (eg, any bodily movement produced by 
skeletal muscles) and exercise (eg, physical activity that is 
planned, structured, repetitive, and purposive) have been 
suggested to mitigate and counteract primary treatment side-
effects10; and have been endorsed by many professional 
organizations such as the American College of Sports 
Medicine,11-14 American Cancer Society,15,16 Spanish Society 
of Medical Oncology,17 and Exercise and Sports Science 
Australia.18,19 Existing guidelines cover exercise recommen-
dations for various types of cancer (eg, lung, prostate, breast, 
lymphoma) and treatment phases (pre-treatment, treatment, 
survivorship, and palliation). However, a substantial gap 
exists for patients with melanoma. For example, it remains 
unclear if exercising pre- or post- melanoma diagnosis is 
associated with any survival benefit,20 although it has been 
shown that these patients are presenting with significant 
reductions in physical activity levels post treatment.21 The 
reduction in physical activity, especially in older adults, 
could increase the risk of sarcopenia as well as cardiovascu-
lar and metabolic diseases.22,23 As commonly observed in 
the aforementioned cancers, it may be that among patients 
with melanoma, exercise promotes significant benefits by 
reducing treatment-related side-effects and enhancing QoL 
through the course of treatment and beyond.
Given the paucity of information regarding physical 
activity and exercise in patients with melanoma, the present 
study aims to systematically review and examine the effects 
of physical activity and exercise on QoL as the primary out-
come, and other objectively-measured (body composition, 
cardiorespiratory fitness, and physical function), and 
patient-reported (fatigue, treatment-related side-effects, 
cognitive function, and psychological distress) outcomes 
among patients with melanoma.
Methods
Study Selection Procedure
The study was undertaken in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement,24,25 and the method used was based 
on the minimum criteria established by the Cochrane Back 
Review Group (CBRG).26 This systematic review was not 
registered in any prospectively systematic review database 
(eg, PROSPERO).
This review included studies reporting on the impact of 
physical activity or exercise interventions on quality of 
life, or other objectively-measured and patient-reported 
outcomes in adult patients with cutaneous melanoma. The 
primary aim of this review was to examine the relationship 
between physical activity or exercise and QoL. The sec-
ondary aims were to evaluate the relationship between 
physical activity or exercise and other objectively-mea-
sured (body composition, and physical function) and 
patient-reported (fatigue, treatment-related side-effects, 
cognitive function, and psychological distress) outcomes. 
Studies were excluded if: (1) they involved mixed cancer 
patients without specific information on results from 
patients with melanoma; (2) they did not include or report 
the specific outcomes included in this review; (3) they 
involved pediatric patients with melanoma, and (4) were 
written in a language other than English. Eligibility was 
assessed and independently evaluated in duplicate, with 
differences resolved by consensus between the 2 reviewers 
(BC and PL), and in case of disagreement, a third reviewer 
(FS) was consulted.
The search was conducted up to February 2021 using the 
following electronic databases: PubMed, CINAHL, 
EMBASE, SPORTDiscus, and Web of Science. The terms 
used were: “Melanoma,” “Physical Activity,” and 
“Exercise” in association with a list of sensitive terms to 
search for experimental studies. We also performed a man-
ual search of the reference lists provided in the selected 
papers. In addition, 2 melanoma-specific systematic 
reviews27,28 that did not specifically focus on patient out-
comes were assessed to detect studies potentially eligible 
for inclusion. The search strategy used is presented in the 
Supplemental Digital Content Appendix 1.
Data Extraction
Titles and abstracts of all articles identified through the 
search strategy were independently evaluated by 2 review-
ers (BC and PL). Abstracts that did not provide sufficient 
information regarding the inclusion criteria were selected 
for full-text evaluation. In the second phase, the same 2 
reviewers independently evaluated these full-text articles 
and selected them in accordance with the eligibility criteria. 
Disagreements between reviewers were resolved by con-
sensus, with a third reviewer (FS) consulted when neces-
sary. The data extraction was performed via a standardized 
form. Descriptive characteristics such as cancer type, par-
ticipant and treatment characteristics, and study outcomes 
were collected.
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Quality Assessment
The quality of all included studies was assessed using the 
McMaster University Critical Appraisal Tool for 
Quantitative Studies.29 This tool includes 16 questions and 
covers the following components: study purpose (Was the 
purpose clearly stated?), literature (Was relevant back-
ground literature reviewed?), design (Is the study design 
appropriate to study aims?, No biases present?), sample 
(Was the sample described in detail?, Was sample size justi-
fied?), outcomes (Were the outcome measures reliable?, 
Were the outcome measures valid?), intervention 
(Intervention was described in detail?, Contamination was 
avoided?, Co-intervention was avoided?), results (Results 
were reported in terms of statistical significance?, Were the 
analysis method(s) appropriate?, Clinical importance was 
reported?, Drop-outs were reported?), and conclusion and 
implications (Conclusions were appropriate given study 
methods and results). Each question was rated and scored as 
1 for yes, 0 for no, and NA for not applicable based on each 
study. A sum score was calculated for each study with 
higher scores indicating higher methodological quality. The 
risk of bias assessment for all included studies was per-
formed independently by 2 reviewers (BC and PL). Any 
disagreements between reviewers were resolved by consen-
sus through discussion with a third reviewer (FS).
Data Synthesis
A narrative/qualitative synthesis was the preferred method 
to provide an overview of the current literature on the topic. 
Given the limited number of eligible trials, heterogeneity of 
study designs, outcomes, and measurement tools, a meta-
analysis was not undertaken. Information extracted from 
studies included participant demographics, health history, 
melanoma stage, treatment type, exercise behavior/physical 
activity levels, and exercise intervention information (fre-
quency, intensity, time, type), as well as information on 
quality of life, fatigue, body composition/weight, physical 
function, treatment-related side-effects, psychological dis-
tress, cognitive function, and lymphoedema. When avail-
able, descriptive data as mean, median, and dispersion 
values (eg, standard deviation, 95% confidence intervals 
[95% CI]) from studies were reported.
Results
Study Selection
Of the 1745 retrieved studies based on the search strategy, 
1209 were retained for screening after duplicate removals. 
Upon evaluation of titles and abstracts, 1157 articles were 
excluded due to their irrelevance for the research question 
and the remaining 52 articles were retrieved in full text for 
further examination. After a comprehensive assessment, 5 
articles30-34 met the criteria to be included in this systematic 
review. In addition, 1 study35 met the inclusion criteria and 
was included based on the manual search. Detailed infor-
mation regarding the process of study selection is shown in 
Figure 1.
Study Characteristics
A total of 882 patients with melanoma, aged 20 to 85 years, 
participated in the 6 included studies.30-35 There was consid-
erable heterogeneity regarding cancer characteristics and 
timing of assessment, with cancer staging ranging from 
stage II to IV. In addition, the timing of study assessment 
was during treatment,32-34 post-treatment,32,35 and 1 to 
10 years following diagnosis30,31 (Table 1). A variety of 
treatments were reported including surgery (3 of 6, 
50%),30,31,35 immunotherapy (2 of 6, 33.3%),32,33 and inter-
feron-alpha (IFN-α) (1 of 6, 16.6%).34 Of the 6 studies 
included in this review, 2 were cross-sectional surveys,30,32 
2 were retrospective analyses,31,35 and 2 were non-random-
ized intervention trials.33,34. Regarding the primary outcome 
of this review, 3 studies included QoL assessment 
(50%),30,31,33 while the remaining assessed treatment-related 
side-effects (eg, lymphoedema) (3 of 6, 50%)31,33,35 fatigue 
(3 of 6, 50%),32-34 body composition (2 of 6, 33.3%),33,34 
physical function (2 of 6, 33.3%),33,34 psychological distress 
(1 of 6, 16.6%),33 and cognitive function (1 of 6, 16.6%).34
Quality Assessment
The quality assessment is presented in Table 2. The overall 
score ranged from 8 to 13 of a total of 16 points (ranging 
from 50% to 81%). All studies30-35 met the criteria related to 
purpose, relevant background, appropriate study design, 
sample description, valid outcome measures, appropriate 
analysis methods, and clinical importance. However, issues 
related to design biases and sample size justification were 
present in all studies. In addition, 3 studies31,33,35 (50%) did 
not report the intervention in detail, or avoid intervention 
contamination or co-intervention. Two studies31,35 did not 
achieve the criteria in the reliability of the outcomes mea-
sure (33.3%), and 1 study did not report the results in terms 
of statistical significance33 (16.7%), while another did not 
provide a conclusion supported by the study methods and 
results.35 Finally, 4 criteria were deemed “not applicable” in 
2 of the studies due to study design. Controlling for inter-
vention contamination, co-intervention, and describing the 
intervention in detail were deemed not applicable in 2 stud-
ies30,32 (33%) while reporting results in terms of statistical 
significance was not applicable in 1 study32 (16.7%).
4 Integrative Cancer Therapies 
Physical Activity Measures and Exercise 
Prescription
Among the included studies, both physical activity behav-
ior and physical activity/exercise interventions were 
explored. In the cross-sectional studies of Blanchard et al30 
and Hyatt et al,32 physical activity behavior was assessed by 
undertaking surveys about weekly physical activities (eg, 
aerobic or resistance training)32 or using the Godin Leisure-
Time Exercise Questionnaire.30 Patients were categorized 
as physically active if they met the recommendations at the 
time from the American Cancer Society (ie, completing 
≥150 minutes of moderate-to-strenuous or 60 minutes of 
strenuous physical activity per week)30 or Clinical Oncology 
Society Australia exercise guidelines (ie, 150 minutes of 
moderate-intensity or 75 minutes of vigorous-intensity 
aerobic exercise and 2 to 3 resistance exercise sessions each 
week).32 In the study by Schwartz et al,34 2 groups of 
patients with melanoma (one group receiving IFN-α and 
another composed of patients who had withdrawn from 
IFN-α treatment within 1 week of commencement) were 
instructed to follow a self-guided aerobic exercise program 
with sessions of 15 to 30 minutes, 4 times a week for a dura-
tion of 4 months. However, given the relevance of IFN-α 
treatment for current clinical practice (ie, no longer recom-
mended for patients with melanoma), only the exercise 
group not on IFN-α treatment34 was considered for further 
analyses in this review. In the remaining 3 studies,31,33,35 
exercise programs were delivered as follows: (1) 60 minute 
sessions, 5 to 7 days (over 1-4 weeks) of multimodal ther-
apy involving exercise with bandages,31,35 followed by 2 to 
3 days per week of 10-minutes self-practice physical 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 Integrative Cancer Therapies 
activity until return of the limb to normal size, and (2) 
8 weeks of multimodal supportive care intervention using 
any combination of aerobic, resistance, qi gong, and yoga 
exercises twice per week.33 No further information regard-
ing physical activity or exercise components were reported.
Outcomes
Quality of life. Three studies reported on QoL using different 
questionnaires including the RAND-36 Health Status 
Inventory Score,30 Istituto Dermopatico Dell’immacolata 
Italian Lymphedema Association questionnaire part II,31 
and the Functional Assessment of Cancer Therapy General 
(FACT-G).33 Based on these reports, localized (stage I and/
or II), regional (stage III), and metastatic (stage IV) mela-
noma survivors in the survey study of Blanchard et al30 
meeting the recommendations36 for a healthy lifestyle (ie, 
physical activity, fruit and vegetable consumption, and non-
smoking) reported higher QoL compared to those not fol-
lowing the recommendation (53.7 ± 8.9 vs 50.6 ± 9.5; 
P < .001). Similar results were observed in the retrospec-
tive study of Carmeli and Bartoletti,31 reporting a statisti-
cally significant association between higher levels of 
physical activity and increased QoL (P < .05) in both local-
ized and regional melanoma survivors. However, changes 
in QoL were not observed in patients with regional and 
metastatic melanoma following 8 weeks of multimodal sup-
portive care in the study by Lacey et al.33
Fatigue. Fatigue was assessed using the FACT-G33 and the 
Schwartz Cancer Fatigue Scale34 in the intervention stud-
ies, while one cross-sectional study32 assessed fatigue with 
the Patient-Reported Outcomes Measurement Information 
System Fatigue–Short Form 7a (PROMIS SF7a) and 
recorded participants’ perspectives with open-ended ques-
tions. Hyatt et al32 reported that among patients with mela-
noma with regional and metastatic disease, fatigue scores 
were slightly higher (54.8 ± 9.0) on the PROMIS SF7a 
than the standardized mean of 50. Additionally, in open-
ended questions from the survey, multiple participants 
attributed experiencing fewer fatigue symptoms during 
treatment to their physical activity/exercise. Compara-
tively, no difference was observed between the interven-
tion and control group in the study of Lacey et al33 
(39.7 ± 8.4 to 40.4 ± 8.8 in the intervention group; 
42.8 ± 7.0 to 43.8 ± 8.8 in the control group) or in the 














 Was the purpose clearly stated? 1 1 1 1 1 1
Literature
 Was relevant background literature reviewed? 1 1 1 1 1 1
Design
 Is the study design appropriate to study aims? 1 1 1 1 1 1
 No biases present? 0 0 0 0 0 0
Sample
 Was the sample described in detail? 1 1 1 1 1 1
 Was sample size justified? 0 0 0 0 0 0
Outcomes
 Were the outcome measures reliable? 1 0 1 0 1 1
 Were the outcome measures valid? 1 1 1 1 1 1
Intervention
 Intervention was described in detail? 1 0 NA 0 NA 0
 Contamination was avoided? 1 0 NA 0 NA 0
 Co-intervention was avoided? 1 0 NA 0 NA 0
Results
 Results were reported in terms of statistical significance? 1 1 1 1 NA 0
 Were the analysis method(s) appropriate? 1 1 1 1 1 1
 Clinical importance was reported? 1 1 1 1 1 1
 Drop-outs were reported? 0 0 0 0 0 1
Conclusion and implications
 Conclusions were appropriate given study methods and results 1 0 1 1 1 1
Total 13/16 8/16 10/13 9/16 9/12 10/16
Abbreviation: NA, not applicable.
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study of Schwartz et al34 (11-18 pts in the intervention 
group), although the effect of exercise was above the mini-
mum clinically important difference of 5 points.37
Body composition and body weight . Lacey et al33 reported 
no change in body fat percentage (from 32.0% ± 11.5% 
to 32.6% ± 11.3%), and a reduction in fat-free mass 
(from 56.7 ± 19.7 kg to 54.1 ± 18.6 kg) after undertak-
ing a tailored multimodal 8-week supportive care inter-
vention, although the assessment method was not 
reported. Both intervention studies33,34 indicated a 
change in body weight; however, neither reported 
within-group statistical significance. Lacey et al33 
observed a reduction in body weight of 1 kg over 
8 weeks, while Schwartz et al34 reported a reduction of 
8.2 kg (85 ± 17.8 kg to 76.8 ± 17.7 kg) after the 4-month 
self-guided exercise intervention.
Physical function. Both intervention studies33,34 evaluated 
physical function before and after the intervention pro-
grams. In addition, Lacey et al33 reported upper and lower 
body muscle strength pre-and post-training of 
32.1 ± 9.4 kg and 37.9 ± 12.3 kg for seated row and 
67.1 ± 17.2 kg and 57.9 ± 19.7 kg for leg press, although 
no statistical comparison was undertaken. To assess car-
diorespiratory capacity (cardiovascular fitness), Lacey 
et al33 utilized a modified Balke treadmill test with deter-
mination of peak oxygen uptake (VO2 peak) and described 
the results for the intervention group as stable (from 
56 ± 30 ml.kg.min−1 to 51 ± 34 ml.kg.min−1) throughout 
the study. Schwartz et al34 evaluated aerobic capacity 
with a 12-minute walk test and concluded that on average 
participants improved by 6% over the 4-month exercise 
intervention period.
Treatment-related side-effects, psychological distress, cogni-
tive function, and lymphoedema. Lacey et al33 examined 
treatment-related side-effects and psychological distress 
in patients with melanoma with regional and metastatic 
disease during treatment. No changes were observed after 
the intervention regarding the Edmonton Symptom 
Assessment Scale (ESAS) and Hospital Anxiety and 
Depression Scale (HADS) over 8 weeks of study dura-
tion. Schwartz et al34 reported cognitive function scores 
relative to the Trail Maker Form A and B. Over the 
4-month study duration, a reduction of 5 seconds for Form 
A and 10 seconds for Form B was observed in exercising 
patients with melanoma.34 A significant reduction in post-
surgery lymphoedema was observed in the retrospective 
studies of Carmeli & Bartoletti31 and Hinrichs et al.35 In 
both studies, patients who undertook the multimodal 
intervention presented significant reductions in lymphoe-
dema assessed by limb volume (average reduction of 
41%, ranging from −6035 to −22%31).
Discussion
In this review, we examined the effectiveness of physical 
activity and exercise on QoL, as well as objectively-mea-
sured and patient-reported outcomes in patients with mela-
noma. The main finding of this review was that physical 
activity/exercise did not adversely impact QoL, or objec-
tively-measured (body composition, physical function, and 
cardiorespiratory fitness) and patient-reported (fatigue, 
treatment-related side-effects, cognitive function, and psy-
chological distress) outcomes in patients with melanoma. In 
addition, major methodological and reporting issues are 
present within many of the currently available studies, high-
lighting a lack of quality research examining the relation-
ship between physical activity/exercise and patient 
outcomes and current treatment side-effects.
Reductions in QoL are common as a result of treatment 
toxicities and are more pronounced in those patients with 
regional and metastatic disease.38-41 While this review did 
not demonstrate that physical activity and exercise have an 
additional effect on QoL, they likely help to maintain QoL 
levels in patients with melanoma during or after treatment. 
Although the previous studies by Blanchard et al30 and 
Carmeli and Bartoletti31 both suggest that in patients with 
melanoma confined to the primary site or with regional dis-
ease physical activity/exercise is significantly associated 
with improved QoL, no significant change in QoL levels 
was observed following 8 weeks of exercise in the interven-
tion study of Lacey et al.33 This result may be related to the 
lack of exercise control as well as having prescribed vastly 
different exercise modalities without supervision. In addi-
tion, this study33 did not present further information regard-
ing the desired or achieved intensities undertaken during 
the exercise program. In previous studies, for example, 
unsupervised exercise programs tend to produce modest 
changes when compared to supervised exercise programs 
on QoL,42 and this may have attenuated the exercise effects 
in patients with melanoma. Furthermore, the poor exercise-
related reporting and lack of supervision also preclude us 
from determining if the minimal exercise stimulus to elicit 
benefits in QoL was achieved in this group of patients.43 In 
this way, despite several studies demonstrating the benefits 
of exercise medicine on QoL in different cancer popula-
tions,37,42,44,45 including metastatic disease,46 methodologi-
cally sound trials with exercise interventions of appropriate 
mode and dosage are needed to determine exercise efficacy 
on QoL in patients with melanoma.
Fatigue is one of the most prevalent symptoms across 
different cancers and treatments,47,48 and although the 
cause is multifactorial there is substantial evidence demon-
strating the role of exercise medicine in reducing this 
symptom across several cancer types.49 In the studies 
included in our review, although physically active patients 
experienced less fatigue as a result of self-guided exercise 
8 Integrative Cancer Therapies 
in the cross-sectional study by Hyatt et al,32 neither of the 2 
included intervention trials33,34 produced meaningful 
changes in this outcome. This is possibly related to the gen-
erally low levels of fatigue presented by the included 
patients with melanoma at baseline. The moderation of this 
outcome by the baseline levels is such that patients respond 
better to the exercise programs if they present with higher 
levels of fatigue.49 Furthermore, another reason may be 
related to the potential mediators of fatigue in cancer 
patients.50,51 Researchers have suggested that both muscle 
mass and inflammatory markers play a role in the fatigue 
reduction observed in prostate50 and breast cancer patients51 
following exercise interventions. However, only one of the 
intervention studies included in this review assessed fat mass 
and lean mass,33 presenting no substantial change in these 
outcomes, while neither measured inflammatory markers.33,34 
This may be considered an important outcome for patients 
with melanoma given the benefits of resistance training pro-
grams on fatigue, muscle mass and metabolic health already 
demonstrated in other cancer populations.37,43
In addition to the contribution of body composition to 
attenuate cancer-related fatigue; muscle and fat mass are 
also associated with physical independence, hospitaliza-
tion, treatment toxicities, and survival outcomes in cancer 
patients.8,52-57 Of the 2 intervention studies included in this 
review, neither reported exercise benefits on muscle mass, 
fat mass or body weight among patients with melanoma,33,34 
which is a concern for this specific patient population, given 
the prevalence of sarcopenia. The prevalence of sarcopenia 
increases ~15% in patients receiving checkpoint inhibitor 
therapy (ipilimumab/PD-1)8 and this represents a major 
issue in terms of overall survival as well as treatment toler-
ance in this group of patients. The maintenance of body 
mass and in particular muscle mass, may be important to 
patients with melanoma with regional or metastatic disease 
who are receiving checkpoint inhibitor therapy given 
improved survival outcomes compared to those presenting 
with drastic reductions during treatment.58 Therefore, treat-
ment-related reductions in body weight could be harmful in 
melanoma patients receiving either targeted therapy or 
immune checkpoint inhibitor therapy which contradicts 
previous reports concerning prostate or breast cancer,59-61 
where a higher body mass negatively impacts treatment and 
survival outcomes. Thus, more research is needed to deter-
mine the effects of exercise on this specific outcome in 
patients with melanoma. Moreover, no meaningful effect 
attributed to physical activity/exercise was observed on 
cognitive function,34 psychological distress,33 physical 
function,34 or even cardiorespiratory fitness33 in the studies 
included in our review. This relates to the likely suboptimal 
exercise programs implemented with these patients (such as 
volume, intensity, and mode of exercise), as such benefits in 
psychological distress, physical function, and cardiorespi-
ratory fitness are consistently demonstrated within other 
cancer types.11,18 With regard to cognitive function, there is 
evidence of aerobic exercise having a positive effect on 
older adults’ cognition, although such effects in patients 
with cancer remains unclear.11
Treatment-related side-effects can impact patients with 
melanoma receiving a variety of treatment modalities. As 
previously mentioned, the addition of checkpoint inhibitor 
therapy to standard care has given rise to a range of irAEs, 
unlike those seen in more traditional treatments.9 In the 
study by Lacey et al,33 immune checkpoint inhibitor treat-
ment-related side-effects and symptoms within the exercise 
group were described as both stable and comparable to the 
standard care control group. This may be related to partici-
pant characteristics; many had previously been treated with 
immunotherapy (82%) and were long-term regional and 
metastatic melanoma survivors with a low symptom load at 
baseline.33 Nevertheless, it appears that over this 8-week 
intervention, exercise did not negatively influence partici-
pants’ irAEs.
Although systemic treatment with immunotherapy or 
targeted therapy is being used increasingly for both regional 
and metastatic melanoma, regional surgery for lymph node 
clearance (whether sentinel or complete lymph node dis-
section) is still commonly used. Complete lymph node dis-
section has been largely abandoned62,63; however, 
lymphoedema remains a potential side-effect of lymph 
node dissection. Lymphoedema is often treated via a multi-
modal approach, including massage, compression ban-
dages/stockings, and specific elastic band exercises.64 Both 
Carmeli & Bartoletti31 and Hinrichs et al35 utilized this 
multimodal approach, reporting significant reductions in 
lymphoedema. However, it is important to note that exer-
cise comprised only one part of a comprehensive therapy. 
Contrary to earlier suggestions, the International Society of 
Lymphology65 describes both vigorous exercise and resis-
tance exercise under controlled conditions (supervised) as 
safe for peripheral lymphoedema patients. In breast cancer 
patients with secondary lymphoedema, both aerobic and 
resistance exercise are safe, while resistance exercise has 
been suggested as being more effective at reducing lymph-
oedema symptoms than usual care.13,66,67 Although compa-
rable lymphoedema symptoms are experienced by patients 
with melanoma, similar trials have not been undertaken in 
this patient population.
To our knowledge, this is the first systematic review 
focusing on the effects of physical activity and exercise in 
patients with melanoma. Given the paucity of the pub-
lished research in this area, a strength of this review is the 
broad inclusion criteria that enabled a comprehensive 
evaluation of relevant publications in this underdeveloped 
field as well as a number of suggestions for future research 
in this patient group. However, some limitations are worthy 
of comment. The small number of included studies with 
various study designs produced significant heterogeneity 
Crosby et al 9
in the present report. For example, the limited evidence 
from physical activity/exercise trials in melanoma patient 
precludes observing trends in this current data, such as 
direction of results indicating benefits derived from physi-
cal activity or exercise programs. In addition, restricted 
outcome reporting and methodological issues also limited 
our conclusions about the efficacy of physical activity/
exercise in patients with melanoma. Therefore, additional 
research is required to examine the effects of exercise 
medicine in this group of patients. Future well-designed 
single group studies with more rigorous exercise interven-
tions and robust reporting are warranted, balancing 
patients’ needs and goals given the range of side-effects 
experienced by patients with melanoma throughout the 
cancer care continuum. Finally, only articles published in 
English were included in this review and this may be con-
sidered a limitation.
In summary, there is some evidence that physical activ-
ity/exercise might present potential benefits in patients with 
melanoma, although major methodological and reporting 
limitations were present in the included studies. Thus, the 
main finding of this systematic review is that physical activ-
ity/exercise did not adversely impact the objectively-mea-
sured or patient-reported outcomes of patients with 
melanoma. This is important to support future research in 
this field examining the exercise effects on QoL, fatigue, 
body composition, physical function, cardiorespiratory fit-
ness, treatment-related side-effects, cognitive function, and 
psychological distress. As a result, future well-designed 
studies examining the role of exercise medicine in patients 
with melanoma are warranted and may potentially enhance 
patient outcomes.
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